Author:
McFarlane Joshua J.,Kochenderfer Mark D.,Olsen Mark R.,Bauer Todd M.,Molina Ana,Hauke Ralph J.,Reeves James A.,Babu Sunil,Van Veldhuizen Peter,Somer Bradley,Gunuganti Vijay,Schnadig Ian,George Saby,Page Ray D.,Arrowsmith Edward,Jain Rohit K.,Zhang Joshua,McHenry M. Brent,Johansen Jennifer L.,Vogelzang Nicholas J.
Funder
Bristol-Myers Squibb Company
Daiichi-Sankyo
Medpacto
Incyte
Mirati Therapeutics
MedImmune
AbbVie
AstraZeneca
MabVax
Stemline Therapeutics
Merck
Lilly
GlaxoSmithKline
Novartis
Genentech
Deciphera
Merrimack
Immunogen
Millennium
Phosplatin Therapeutics
Calithera Biosciences
Kolltan Pharmaceuticals
Principa Biopharma
Peloton Pharmaceuticals
Immunocore
Roche
Aileron Therapeutics
Amgen
Onyx
Sanofi
Boehringer Ingelheim
Astellas Pharma
Five Prime Therapeutics
Jacobio
Top Alliance BioScience
Janssen
Clovis Oncology
Takeda
Karyopharm Therapeutics
Foundation Medicine
ARMO Biosciences
Pfizer
Loxo
Sarah Cannon Research Institute
Eli Lilly
Tesaro
TG Therapeutics
Celgene
BMS
Boston Biomedical Inc
Novocure
Guardant Health
Acerta Pharma
Rhizen Pharmaceuticals
Takeda Pharmaceuticals
Onconova Therapeutics
CTI Biopharma
Bayer
Corvus
Acceleron
Agensys
Eisai
Reference15 articles.
1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
3. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial;Cella;Lancet Oncol,2016
4. OPDIVO (nivolumab),2019
5. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†;Escudier;Ann Oncol,2019